Background: Administrative healthcare databases are increasingly used for health services and comparative effectiveness research. When comparing outcomes between different treatments, interventions, or exposures, the ability to adjust for differences in the risk of the outcome occurring between treatment groups is important. Similarly, when conducting healthcare provider profiling, adequate risk-adjustment is necessary for conclusions about provider performance to be valid. There are limited validated methods for risk adjustment in ambulatory populations using administrative healthcare databases.
T he ability to characterize the comorbidity burden of a population is of great importance in many areas of health services and comparative effectiveness research. When using observational or nonrandomized studies to compare outcomes between subjects receiving different treatments, exposures, or interventions, the ability to adjust for systematic differences in outcome risk between treatment groups can reduce bias when comparing outcomes between treatment groups. Furthermore, adjusting for comorbidity burden allows for valid riskadjusted estimates of the performance of different healthcare providers. 1 Several methods have been derived for summarizing the comorbidity burden of a patient population using administrative data. Charlson et al 2 derived and validated a weighted index of comorbidities for predicting mortality in hospitalized general medical patients, which was subsequently adapted by Deyo et al 3 for use with the International Classification of Diseases (ICD-9-CM) diagnosis and procedure codes that are frequently used in electronic healthcare administrative data. The use of the Deyo-Charlson comorbidity index for risk adjustment is ubiquitous in health services research. Similarly, Elixhauser et al 4 developed a method to classify comorbidities in hospitalized patients using diagnoses coded using the ICD-9-CM diagnosis codes in administrative data. Both of these schemes have been updated for use with the ICD-10 diagnosis classification scheme. 5, 6 Schneeweiss et al 7 proposed that the number of unique drugs prescribed to be used for riskadjustment purposes. Another method used for risk adjustment is the Chronic Disease Score, which uses outpatient pharmacy records. 8 A limitation of the former 2 approaches is their reliance on hospitalization records, which limits their utility in ambulatory populations of patients. A limitation of the latter 2 methods is their use of prescription records. In many jurisdictions, data on drug prescribing are not available for the entire population.
The Johns Hopkins Adjusted Clinical Groups (ACGs) are a person-focused, diagnosis-based method of categorizing subjects' illnesses. The ACG system assigns each ICD code (9 version, 9-CM version, or 10 version) to 1 of 32 diagnosis clusters known as Aggregated Diagnosis Groups (ADG). Individual diseases or conditions are placed into a single ADG based on 5 clinical dimensions: duration of the condition, severity of the condition, diagnostic certainty, etiology of the condition, and specialty care involvement. [9] [10] [11] [12] ICD codes within the same ADG are similar in both clinical criteria and expected need for healthcare resource. Each individual may have diagnoses belonging to between 0 and 32 ADGs. The 32 ADGs can be collapsed into 12 Collapsed ADGs (CADGs). As with the ADGs, a given diagnosis belongs in only 1 CADG; however, subjects can have multiple diagnoses, each of which can be within different CADGs. Finally, subjects are assigned to exactly 1 of 106 ACGs. Subjects within the same ACG are expected to have similar healthcare resource utilization. The reader is referred elsewhere for a greater discussion of the ADG and ACG methodology. [9] [10] [11] [12] Importantly, the ADG/ACG definitions do not rely solely on the use of inpatient health administrative data, but also use data contained in ambulatory healthcare data. Thus, ICD diagnosis codes obtained from physician billing claims can be used in addition to ICD diagnosis codes contained in electronic hospital discharge abstracts.
The Johns Hopkins ADGs and ACGs were developed for predicting healthcare resource utilization. Several studies have examined the ability of these classifications to predict healthcare use. However, there is a paucity of research into the ability of these comorbidity classification schemes to predict mortality. A few studies have examined the ability of the Johns Hopkins ACGs to predict mortality. [13] [14] [15] [16] [17] Depending on the patient population and the duration of follow-up for determining mortality, c-statistics for models that included the ACGs in addition to age and/or sex ranged from 0.701 to 0.768. To the best of our knowledge, no studies have examined the ability of the ADG comorbidity classification scheme to predict mortality. There are fewer ADGs than there are categories in the ACG classification. There are 2 potential advantages to the use of ADGs to predict mortality compared with the use of ACGs. First, there is the potential for more parsimonious regression models. Second, as patient risk may be related to multiple conditions and there are 2 32 possible combinations of ADGs, use of the ADGs may permit more accurate mortality prediction compared with the use of the ACGs.
There is increasing interest in using administrative healthcare data to compare the effects of treatments, interventions, or exposures in nonhospitalized or ambulatory populations. Mortality is an outcome that is frequently used in health services and comparative effectiveness research. The objective of this study was to determine whether ADGs can be used to accurately predict mortality in a general adult population cohort.
METHODS

Data Sources
In the Canadian province of Ontario, all medically necessary services are provided within a single-payor public healthcare system, with no parallel private system. The Ontario Health Insurance Plan (OHIP) is a governmentfunded universal health insurance program that funds physician services, whereas hospital, long-term care, and home care services are funded by the Ministry of Health and Long-Term Care. These services are provided to all residents of Ontario, without deductibles or copayments. Furthermore, prescription drug coverage is provided to all residents above the age of 65 years and to those on social assistance.
We used 4 different population-based administrative healthcare databases that were linked by encrypted health number. The Registered Persons Database (RPDB) contains basic demographic information on all Ontarians who were ever eligible for Ontario's universal healthcare insurance program. The RPDB contains information on each resident's date of birth, sex, and date of death (if applicable). The Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD) contains information on all inpatient hospitalizations in the province of Ontario. For each hospitalization record, there are 25 fields for recording diagnoses made on the patient during the course of the hospitalization. Since 2002, diagnoses have been coded using the ICD 10th revision coding scheme. The OHIP physician billing database contains billing claims submitted by Ontario physicians to the provincial universal health insurance program. Each claim contains a fee code describing the type of service provided, and a diagnosis code denoting a reason for the service. The diagnosis field is coded using a truncated version of the ICD-9 coding scheme. 18 The Ontario Mental Health Reporting System (OMHRS) collects data on patients in adult-designated inpatient mental health beds. This includes beds in general, provincial psychiatric, and specialty psychiatric facilities. The OMHRS contains data on reasons for admission and for discharge and on psychiatric and nonpsychiatric diagnoses.
Study Subjects
The study sample consisted of all subjects in the RPDB who were alive and eligible on their birthday in 2007. Each subject's birthday in 2007 served as the subject-specific index date. We excluded subjects who were aged below 20 years or above 100 years on the index date. For each subject, we determined whether they died within the 365 days after their index date.
For each subject, we identified all diagnoses associated with all hospital admissions from the CIHI DAD and all physician billing claims in the OHIP database for physician services provided in 2 years before the index date. For each subject, we used the Johns Hopkins ACG software program to collapse these diagnoses to the 32 ADGs. Thus, for each subject, we determined whether an ICD diagnosis code within each of the 32 ADGs had occurred in 2 years before the index date.
Statistical Methods
For each of the 32 ADGs, we compared the probability of death within 365 days of the index date for those with and without diagnoses in the given ADG using the w 2 test.
To evaluate the performance of ADG-based methods for predicting mortality in a sample that was independent of the sample in which regression models were derived, we used a random number generator to divide the overall sample into approximately equally sized derivation and validation samples. Using the subjects in the derivation sample, we used logistic regression to regress the occurrence of death within 365 days of the index date on age (assuming a linear relationship between age and the log-odds of death), sex, and 32 indicator variables representing the presence or absence of the 32 ADGs. This model will be called the "full logistic regression model." Backwards variable elimination with a significance level of 0.05 for variable retention was used to develop a parsimonious logistic regression model for predicting mortality. The resultant model will be called the "final logistic regression model."
Model discrimination in the derivation sample was assessed using the c-statistic. 19 We used the final logistic regression model to obtain the predicted probability of mortality for each subject in the validation sample. The predictive accuracy of the model developed in the derivation sample was assessed in the validation sample using the c-statistic.
Model calibration was assessed in several manners. First, using the final logistic regression model, predicted probabilities of mortality were obtained for each subject in the validation sample. The validation sample was divided into 100 approximately equally sized groups using the centiles of predicted probability of mortality (each centile in the validation sample consisted of approximately 52,500 subjects). Within each of the 100 groups in the validation sample, we determined both the mean predicted probability of mortality based on the final logistic regression model and the observed probability of mortality amongst subjects in that group. The relationship between observed and predicted mortality was then examined graphically. Second, calibration-in-the-large was determined. 20 Calibration-in-the-large compares the mean predicted probability of death in the validation sample with the observed probability of mortality in the validation sample. Third, we determined the calibration slope (deviation of the calibration slope from unity denotes miscalibration). 20 To do so, we used logistic regression to regress the occurrence of death within 1 year of the index date in the validation sample on the linear predictor of mortality obtained using the regression coefficients from the final logistic regression model (estimated in the derivation sample) applied to the subjects in the validation sample. To determine whether the performance of the full logistic regression was solely because of age and sex, we repeated the above process with a regression model that included only age and sex. We also repeated the above process with a regression model that only contained indicator variables for the 32 ADGs and that excluded age and sex.
Analyses in health services research and pharmacoepidemiology are often restricted to those above the age of 65 years, as these subjects are eligible for Medicare in the United States and for provincial drug insurance coverage in Ontario. To determine whether the final logistic regression model performed differently in different age strata, we stratified each of the derivation and validation samples into 2 strata. The first stratum consisted of subjects aged below 65 years, whereas the second stratum consisted of subjects aged 65 years and above. Within each of the 2 strata in the derivation sample, we reestimated the coefficients for the final logistic regression model. We then obtained predictions of the probability of death within 365 days for each subject in each of the 2 strata in the validation sample. The predictive accuracy of the final regression model was assessed in each stratum in the validation sample using the c-statistic.
Health services use is heavy during the final year of life. 21, 22 We conducted a sensitivity analysis to address the concern that increased health services use during the last year of life would give rise to the opportunity for greater documentation of comorbidity. We excluded subjects who died within 365 days of their index date. In the sample of all subjects who survived for at least 1 year from their index date, we examined the ability of our final logistic regression model to predict the occurrence of death between 366 and 730 days after the index date. Methods similar to those described above were used for this sensitivity analysis.
Finally, for comparative purposes, we examined the ability of 2 alternative comorbidity coding schemes to predict 1-year mortality in our overall population cohort. First, we calculated the Charlson comorbidity index 3,5 and the Elixhauser comorbidities 4,5 using data from hospitalization occurring in 2 years before the index date (alternatively, researchers may include out-patient records in addition to inpatient records when determining whether a given comorbidity was present 23 ). Diagnoses for coding the Charlson comorbidity index were obtained from the CIHI DAD. For the Elixhauser comorbidities, diagnoses were obtained from the CIHI DAD. For mental and addiction Elixhauser comorbidities, the OMHRS database was also used to identify occurrences of the given diagnoses. Subjects who had not been hospitalized in the previous 2 years had their Charlson score set to zero. Similarly, these subjects had their values of each of the 30 Elixhauser comorbidities set to absent. For the Charlson comorbidity score, a logistic regression model to predict the probability of 1-year mortality using the Charlson comorbidity index and age and sex was developed in the derivation sample. For the Elixhauser comorbidities, the coefficients for a logistic regression model with age, sex, and indicator variables for the 30 Elixhauser comorbidities were estimated in the derivation sample. The accuracy of each of these 2 models was assessed in the validation sample using the c-statistic.
RESULTS
The study sample consisted of 10,498,413 subjects between the ages of 20 and 100 years. The median age was 46 years (25th and 75th percentiles: 34 and 59 y, respec-
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Medical Care Volume 49, Number 10, October 2011 tively). Women comprised 51% of the study sample. The prevalence of each of the 32 ADGs in the study sample is described in Table 1 . The prevalence of the individual ADGs ranged from a low of 0.5% (ADG: see and reassure) to a high of 43.8% (ADG: signs/symptoms: uncertain). Note that as the ADGs are not mutually exclusive, subjects with a diagnosis in a given ADG can also have diagnoses within other ADGs. Although 43.8% of subjects had at least 1 diagnosis within the latter ADG (ADG: signs/symptoms: uncertain), only 0.8% of subjects had diagnoses that lay solely within this ADG. The number of distinct ADGs in which subjects had diagnoses ranged from 0 (15.4% of subjects) to 25 (<6 of subjects). The median number of distinct ADG categories was 4 (the 25th and 75th percentiles were 2 and 7, respectively), whereas 95% of subjects had diagnoses in 11 or fewer ADGs. Overall, 85,007 (0.81%) subjects died within 365 days of their index date. The 1-year mortality rate for those with and without each ADG is described in Table 1 . For all 32 of ADGs, there was a statistically significantly difference in the probability of mortality between those with and without the ADG (P<0.001). The statistical significance of many of these associations may be driven primarily by the very large size of our population sample.
The predictive accuracy of the different regression models are summarized in Table 2 . The c-statistic of the full logistic regression model (age, sex, and indicator variables for the 32 ADGs) was 0.917 in both the derivation and To assess the sensitivity of this finding to the particular split of the sample, we repeatedly split the original sample into derivation and validation samples 100 times. In each derivation sample, we estimated the coefficients of the final regression model and applied these coefficients to the corresponding validation sample. The c-statistics ranged from 0.915 to 0.919, with a median of 0.917.
The adjusted odds ratios for the association between age, sex, and the 28 ADGs and 1-year mortality in the derivation sample are reported in Table 3 . The adjusted odds ratios for the 28 ADGs ranged from a low of 0.656 (ADG: chronic specialty: unstableFear, nose, throat) to a high of 2.880 (ADG: psychosocial: recurrent or persistent, unstable).
The final logistic regression model predicted probabilities of 1-year mortality for each subject in the derivation sample. These predicted probabilities ranged from a low of 0.000023 to a high of 0.8975. The relationship between the observed probability of death and the mean predicted probability of death across the 100 strata determined by the centiles of predicted probability of death in the validation sample is described in the left panel of Figure 1 . A dotted diagonal line has been superimposed in Figure 1 . Points on this diagonal line denote perfect concordance between observed and predicted mortality. In the 94 subgroups with the lowest mean predicted probability of death, there was almost perfect concordance between the mean predicted probability of death and the proportion of subjects who died The effect of each variable listed in Table 3 is adjusted for all other variables in Table 3 .
ADG indicates Aggregated Diagnosis Group.
within 1 year of the index date. In all but the top 3 strata, the absolute difference between the observed probability of death and the mean predicted probability of death was less than 0.01. In the highest 3 strata, the difference between the observed probability of death and the mean predicted probability of death were 0.0141, 0.0175, and À 0.0344, respectively. Across the 100 strata, the median difference between the observed probability of death and the mean predicted probability of death was À 0.00025 (25th and 75th percentiles: À 0.00044 and 0.00004, respectively). We repeated the process of dividing the sample into derivation and validation components 4 additional times and determined the calibration of the model in the validation sample after estimating the regression coefficients in the derivation sample. The 4 resultant calibration plots were indistinguishable from that presented in the left panel of Figure 1 .The center and right panels of Figure 1 depict the concordance between predicted and observed mortality for the Charlson and Elixhauser methods, respectively. Both of these methods had calibration that was comparable with that of the ADG model. The final logistic regression model showed excellent calibration-in-the-large, with an intercept of 0.0066 (95% confidence interval: À 0.0035-0.0166). The difference in log-odds between predictions and observed outcomes was not statistically significantly different from zero (P = 0.2014). The calibration slope was equal to 0.9961 (95% confidence interval: 0.9903-1.0019). Thus, the final logistic regression model displayed no lack of calibration in the validation sample. The Charlson and Elixhauser models displayed acceptable calibration-in-the-large and calibration slopes that were not different from 1.
We examined the performance of the final logistic regression model in subjects below the age of 65 years. The c-statistic of the final logistic regression model was 0.824 and 0.819 in the derivation and validation samples, respectively. In subjects above the age of 65 years, the c-statistic of the final logistic regression model was 0.816 and 0.814 in the derivation and validation samples, respectively. We speculate that the decreased discrimination when the sample was stratified by age was because of fewer individual differences in demographic and diagnostic profiles in the more homogeneous subsamples.
After excluding subjects who died within 365 days of their index date, the c-statistic of the final logistic regression model when used for predicting the probability of mortality between 366 and 730 days of the index date was 0.905 in both the derivation and validation samples.
DISCUSSION
We examined the ability of logistic regression models using age, sex, and the Johns Hopkins ADGs to predict the probability of death within 1 year in a general population cohort. We used a large, population-based sample consisting of all Ontarians between the ages of 20 and 100 years who were alive on their birthday in 2007. We found that logistic regression models based on age, sex, and the ADGs accurately predicted mortality in this population sample. A logistic regression model consisting of age, sex, and 28 ADGs had excellent discrimination and calibration. In a review of comorbidity scores to control for confounding in administrative database research, Schneeweiss and Maclure 24 found that the c-statistics for 4 versions of the Charlson score and 2 versions of the Chronic Disease Score ranged, depending on the population and exposure, from 0.64 to 0.77 for in-hospital or 30-day mortality. Although our study population consisted of ambulatory patients, the performance of ADGs for predicting mortality performed very favorably compared with that of previous comorbidity scores for predicting mortality.
One advantage of using the Johns Hopkins ADGs is its application to nonhospitalized cohorts. Adaptations of the Charlson comorbidity index for use with ICD-9-CM or ICD-10 diagnostic codes are frequently used for comorbidity adjustment when estimating effects of exposures and treatments using administrative healthcare data, or for comparing outcomes across different healthcare providers. However, the original Charlson comorbidity score was derived in hospitalized general medical patients, and was initially validated in female oncology patients. 3 Furthermore, coding of the Deyo-Charlson index is designed for settings in which all subjects have been hospitalized, limiting its utility in ambulatory subjects. In contrast, ADGs can be determined for all subjects who have accessed the healthcare system, whether in an ambulatory setting or in a hospital setting. This permits comorbidity adjustment to be conducted in ambulatory populations and in hospitalized populations. For comparative purposes, we examined the predictive ability of logistic regression models that incorporated the Charlson comorbidity index or the Elixhauser comorbidities using data obtained from hospitalizations in 2 years before the index date. We found that the use of these 2 models resulted in a minor decrease in discrimination compared with the model that incorporated the ADGs. However, calibration was approximately comparable across the 3 methods. Furthermore, it should be noted that use of a logistic regression model consisting of only age and sex resulted in only a modest decrease in discrimination compared with the other 3 regression models.
When choosing between risk adjustment based on ADGs and risk adjustment based on either the Charlson or Elixhauser comorbidities, one must consider several competing issues. Arguments in favor of an approach based on the ADGs include the minor increase in discrimination compared with the latter 2 approaches. Furthermore, the use of ADGs may have greater face validity as the ACG/ADG system was not designed primarily for use in hospitalized patients. Arguments in favor of the latter 2 approaches include the fact that the use of the ADGs requires a user license which typically requires a fee, whereas the Charlson and Elixhauser coding algorithms are nonproprietary and can be used without payment. It should be noted that the fee for using the ACG software may be nominal when used for research or academic purposes. A further relative disadvantage to the use of ADGs is that the assignment of ICD-9/10 diagnosis codes to ADGs is through a proprietary algorithm. Thus, the ADGs may be less transparent than the Charlson and Elixhauser comorbidity adjustment methods, for which the assignment of ICD-9/10 codes to different categories is explicitly described. As a consequence, it may difficult for researchers using the ADGs to fully explore their data so as to understand their results. Despite this lack of transparency, ACGs have been successfully used to predict mortality in several patient populations. [13] [14] [15] [16] We have shown that the ADGs can be used to accurately predict 1-year mortality in a general population cohort. However, their utility for predicting mortality in specific disease populations or for predicting other outcomes needs to be examined in future studies. When regression models using age, sex, and the ADGs are used for predicting mortality in other general population cohorts, we recommend that researchers recalibrate the model by estimating the regression coefficients in their specific populations, rather than using regression coefficients estimated in our sample.
In conclusion, a logistic regression model that used age, sex, and the Johns Hopkins ADGs accurately predicted mortality in a general population cohort. This method may be useful for risk or comorbidity adjustments in health services research when comparing mortality between healthcare providers or when using observational studies to estimate the effects of exposures, treatments, and interventions on mortality.
